Early Trials: Johnson & Johnson COVID Vaccine Prompts Immune Response

The Johnson & Johnson vaccine, using an adenovirus to deliver the coronavirus spike protein, has shown promising results in early clinical trials. It generates an immune response in both young and elderly volunteers, with 90% producing antibodies within 29 days. The vaccine is advantageous due to its single-dose nature and less stringent storage requirements compared to Pfizer and Moderna vaccines. Phase 3 trials will provide more insights, and J&J plans to seek FDA emergency approval soon.

How does the Johnson & Johnson vaccine differ from the mRNA vaccines?

• It uses a protein subunit to deliver the spike protein.

• It uses a DNA plasmid to deliver the spike protein.

• It uses a common cold virus to deliver the spike protein.

• It uses a live virus to deliver the spike protein.

What percentage of volunteers developed neutralizing antibodies 29 days after receiving the Johnson & Johnson vaccine?

• 100%

• 90%

• 80%

• 70%

Which age group showed stable antibody levels for at least 71 days?

• 18 to 55

• 65 and older

• 55 to 65

• All age groups

What is a major advantage of the Johnson & Johnson vaccine compared to Pfizer and Moderna vaccines?

• It has no side effects.

• It is a single-dose vaccine.

• It can be stored at room temperature.

• It requires two doses.

When does Johnson & Johnson plan to release their phase 3 trial results?

• Next week

• Next year

• Next month

• Next quarter